Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
H3 mRNA/LNP Vaccine by Sanofi for Influenza A Virus, H3N2 Subtype Infections: Likelihood of Approval
H3 mRNA/LNP Vaccine is under clinical development by Sanofi and currently in Phase I for Influenza A Virus, H3N2 Subtype...